Articles tagged with Macular Degeneration
Researchers at Tufts University School of Medicine developed a gene therapy approach that significantly reduces uncontrolled blood vessel growth and cell death typical of AMD, slowing its progression. The treatment uses CD59 to block the formation of 'membrane attack complex' in cell membranes.
Women under 75 with high vitamin D levels have lower risk of early age-related macular degeneration (AMD), while those with low levels are at increased risk. The study found that women with 25-hydroxyvitamin D concentrations above 38 nanomoles per liter had a 44% decreased odds of developing AMD.
Research suggests that high vitamin D levels are associated with a reduced risk of early age-related macular degeneration (AMD) in women under 75. Higher vitamin D intake from food and supplements is linked to lower AMD risk, while sun exposure does not show a significant correlation.
Researchers at Georgetown University Medical Center have successfully created retinal cells derived from human-induced pluripotent stem cells that mimic the eye cells responsible for age-related macular degeneration. The discovery paves the way for potential treatment and regeneration therapies for this debilitating condition.
A large population study found that regular consumption of fish and omega-3 fatty acids was associated with a significantly reduced risk of developing age-related macular degeneration in women. The study, published in Archives of Ophthalmology, found that higher intake of DHA and EPA was linked to a 38% lower risk of the condition.
Research finds late-stage age-related macular degeneration associated with a 56% increased risk of any type of stroke. Specifically, late AMD was strongly linked to over six times the risk of brain hemorrhage but not with brain infarction, according to a study presented at the American Stroke Association's International Stroke Conference.
The study found an estimated 6.5% of Americans aged 40 and older have age-related macular degeneration, a decline from the 1988-1994 survey's 9.4%. Non-Hispanic black individuals had lower AMD prevalence than non-Hispanic white individuals.
The Ontario Genomics Institute is investing in ArcticDx's Macula Risk test, which detects genetic variations predicting AMD progression. The test may help target effective care to those who need it most and relieve uncertainty for others.
Researchers at Medical College of Georgia are investigating a link between hemochromatosis and the wet form of macular degeneration. They suspect that excessive iron levels accelerate aging in the eyes, leading to increased risk of vision loss.
Early-stage age-related macular degeneration is associated with modifiable risk factors like smoking and low HDL cholesterol. The study found that the condition becomes more common with age, especially in those over 65, while lower HDL cholesterol levels increase the risk.
The use of intravitreal injections has grown significantly in Canada, but only a small proportion of ophthalmologists perform the procedure. The majority of injections are performed by a small group of providers, highlighting concerns about access to treatment.
Researchers discovered that crowding does not make peripheral vision random, but rather creates a 'blending' effect that makes the world appear more regular. This process can help improve the recognition of objects in crowded environments for people with central vision loss due to eye diseases.
Researchers at Columbia University Irving Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. The study showed promising results, with one-fourth of the mice regaining vision after receiving the stem cells.
A recent study by Kaiser Permanente has compared the effectiveness of two AMD drugs, ranibizumab (Lucentis) and bevacizumab (Avastin), while a global report highlights retinal vein occlusion prevalence worldwide. Additionally, research reveals that central vision impairment significantly increases the risk of falls in older adults.
A study found no association between cataract surgery and worsening of age-related macular degeneration in individuals with non-neovascular AMD. The rate of progression to advanced AMD was similar among participants' other, cataract-free eyes over time.
Scientists found that a lack of diffusible VEGF causes retinal defects like geographic atrophy, which may impact the use of anti-VEGF drugs for wet macular degeneration. The study increases understanding of AMD's causes and offers potential new therapies.
A study found that anti-VEGF treatment for wet age-related macular degeneration can lead to increased intraocular pressure in patients without a family history of glaucoma. A new low-cost vision screening method, using an auto-refractor and pre-made eyeglasses, has shown promise in improving vision for millions in developing countries.
Researchers found no significant difference in visual outcomes between Bevacizumab and Ranibizumab treatments for age-related macular degeneration after 6 months. The study suggests that both drugs are effective, with Bevacizumab being a more affordable option.
Research highlights improved vision in type 1 diabetes patients, a link between macular degeneration and coronary heart disease, and the impact of vision on well-being across the lifespan. Effective treatments and better management of blood glucose levels contribute to the positive trend.
Scientists have designed a painless microneedle patch that can deliver vaccines and medications through the skin, offering a potential solution to painful injections. The patch uses tiny 'microneedles' to improve treatment of diseases such as diabetes and macular degeneration.
A diet high in omega-3 fatty acids has been found to protect against a variety of diseases, including age-related macular degeneration. The study suggests that a diet enriched in EPA and DHA can ameliorate the progression of retinal lesions in a mouse model of AMD.
A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD). The marker, CCR3, shows strong potential as a means for both early detection and preventive treatment.
Two reports in Archives of Ophthalmology found that consuming omega-3 fatty acids from fish, nuts, and olive oil was associated with a lower risk of age-related macular degeneration. Eating one serving of fish per week reduced the risk by 31%, while consuming one to two servings of nuts lowered it by 35%.
A new MIT study sheds light on the underlying neural mechanism of macular degeneration, revealing that deprived neurons respond equally to stimuli at both preferred and non-preferred locations. The findings suggest a relatively passive response to visual deprivation.
Researchers have imaged the nearly invisible layer of retinal pigment epithelial cells in a living eye, which could help diagnose macular degeneration at an early stage. This breakthrough technique uses fluorescent chemicals produced by the cells to detect potential disease before symptoms appear.
Two studies tracked 31,000 runners for seven years and found that running reduced the risk of cataracts and age-related macular degeneration. Vigorous exercise may be a key factor in preventing eye disease, particularly among men who ran more than 5.7 miles per day.
A new study shows that brain activity increases in the visual cortex when patients with macular degeneration focus on using other parts of their retina to compensate for their loss of central vision. The brain reorganizes its neural connections to process information from other parts of the eye.
A population-based study of Type 1 diabetes patients found that better glycemic control reduces diabetic retinopathy progression. Additionally, a cohort study on age-related macular degeneration (AMD) discovered an association between poor night vision and increased risk of AMD progression.
A new laboratory-engineered mouse model shows slowed AMD progression with retinylamine treatment, providing biochemical evidence for a potential therapeutic intervention. Researchers aim to prevent rapid eye degeneration and slow disease advancement.
Researchers have identified a gene variant linked to protection against age-related macular degeneration (AMD), which affects the retina and choroid layer. The study suggests that a malfunctioning innate immune system is contributing to the disease, providing potential targets for novel treatments.
A genetic association with SERPING1 has been found to be strongly linked to age-related macular degeneration, a leading cause of visual impairment and blindness. The study's findings have significant implications for the development of novel treatments for this devastating disease.
A new study found that an experimental therapy for age-related macular degeneration may have adverse effects on patients with a certain genetic mutation. The therapy uses RNA interference to silence disease-causing genes, but this approach may not be suitable for everyone due to individual genetic differences.
Scientists have identified the protein SR-B1 as responsible for transporting lutein and zeaxanthin, two nutrients that may help prevent macular degeneration. The study found that blocking the protein's action significantly reduced the cells' absorption of these nutrients.
Research found that postmenopausal hormone users had a 48% lower risk of neovascular AMD, but unexpectedly higher risk of early AMD. Women who gave birth had a 26% lower risk of early AMD.
A study published in PLoS Medicine found that CD36 deficiency leads to choroidal involution, a key feature of dry age-related macular degeneration. The research also showed that COX-2 down-regulation plays a crucial role in this process.
A long-term study found that smokers have an increased risk of developing early age-related macular degeneration (AMD) and experience greater progression of the disease. Smokers developed AMD at a younger age than non-smokers, and smoking was associated with cumulative progression of AMD over 15 years.
Researchers discovered that experimental drug endostatin may significantly reduce or eliminate abnormal blood vessel growth, a hallmark of advanced AMD. This finding gives hope to individuals at high risk for the disease, which affects central vision and can lead to total blindness.
Scientists have developed a mouse model of age-related macular degeneration to study the disease's progression and develop potential treatments. The model, caused by a mutation known to produce AMD in people, will help researchers understand the biochemical details of how AMD occurs.
Consuming higher levels of lutein and zeaxanthin may be associated with a reduced risk for age-related macular degeneration. The study found that participants who consumed more of these yellow plant pigments had lower rates of advanced AMD and large or numerous intermediate drusen.
Researchers at George Mason University found that zinc deposits are hallmarks of age-related macular degeneration (AMD), a condition affecting millions of Americans. The study suggests that excessive zinc intake may contribute to AMD progression.
Current and past smokers are at increased risk of developing late-age related macular degeneration, with current smokers four times more likely than non-smokers. Smoking's link to AMD is thought to share other risk factors with cardiovascular disease, including high cholesterol levels and hypertension.
A gene variant in the complement C3 gene has been found to more than double the risk of developing age-related macular degeneration, a leading cause of visual loss and blindness. The study, published in the New England Journal of Medicine, suggests that inflammation plays a key role in the disease process.
Individuals aged 49 and older with cataract or age-related macular degeneration have higher mortality rates compared to those without visual impairments. Regular vision assessment may lead to early detection and treatment to reduce the impact of visual impairment.
The National Institute for Health and Clinical Excellence (NICE) proposes restricting use of ranibizumab and pegaptanib to patients who have gone blind in one eye. However, the Drug and Therapeutics Bulletin concludes that this approach is 'unacceptable' and calls for universal access to these sight-saving drugs. NICE has also not issu...
Dr. Jayakrishna Ambati's research on macular degeneration has led to a breakthrough discovery that may help patients fight the condition. With a $750,000 grant, Ambati will develop a phase 1 clinical trial to test new therapies for age-related macular degeneration.
A study by Schepens Eye Research Institute found that an educational video increased patients' knowledge about macular degeneration and adaptive devices, but had no effect on their emotional response or behavior. The video did not motivate patients to make changes to improve their quality of life.
Researchers at Yale University have found a gene variant that increases the risk of developing aggressive 'wet' age-related macular degeneration, the most common cause of blindness in people over 50. The study found a single nucleotide polymorphism (SNP) in the HTRA1 gene on chromosome 10 associated with greatly increased risk of wet AMD.
A large study found that regular physical activity can reduce the likelihood of developing age-related macular degeneration by up to 70%. Participants with active lifestyles were less likely to develop the condition, with regular walkers experiencing a 30% lower risk.
The Age-Related Eye Disease Study 2 investigates nutrient-based factors influencing AMD progression. Dr. Yu-Guang He hopes the study will resolve the potential benefit of supplements for AMD, which affects nearly 7 million Americans.
Researchers have discovered a new gene, HTRA1, that significantly increases the risk of developing Age Related Macular Degeneration. This discovery may lead to new treatments and preventive strategies for patients with AMD.
Two large clinical trials show ranibizumab's effectiveness in treating neovascular macular degeneration, but its high cost raises questions about the value of comparing it to bevacizumab, a cheaper alternative. Bevacizumab, originally designed for cancer treatment, also appears to be effective in treating this eye disease.
Researchers found that macrophage entry into the eye encourages new vessel formation, while direct injection of macrophages significantly inhibits this process. This suggests regulators of macrophages may be a possible therapeutic target in AMD.
Dr. Ambati, a University of Kentucky researcher, has received the prestigious 2006 Lew R. Wasserman Award for his work on age-related macular degeneration. The award comes with a $55,000 grant to support his research and will be used to hire additional staff.
A genetic variation in the CFH gene is associated with an increased risk of age-related macular degeneration (AMD). The study found that individuals with the mutation had a 48% cumulative risk of developing late AMD by age 95, while those without it had a lower risk.
Apolipoprotein E (apoE) may play a role in age-related macular degeneration, despite its link to Alzheimer's disease. The study aims to understand why apoE-4 correlates with reduced incidence of macular degeneration.
A study of elderly male twins found that eating fish frequently may decrease the risk of age-related macular degeneration, while smoking nearly doubles the risk. The benefits were most apparent among individuals who consumed two or more servings of fish per week.
Women with high-glycemic-index diets had greater risk of early AMD, regardless of total carbohydrate intake. Dietary quality, not quantity, may play a crucial role in AMD development.
A study of 2,946 patients with age-related macular degeneration (AMD) found that those with more severe AMD had poorer cognitive function and lower brain reserve. This association remained even after controlling for other factors, suggesting a link between vision and cognitive impairment.
A UK researcher found that VEGF promotes angiogenesis in macular degeneration, but also has an anti-angiogenic effect via SPARC. Controlling SPARC levels may be key to controlling angiogenesis in diseases like cancer. This discovery opens new avenues for treating diseases related to angiogenesis.
A University of Kentucky researcher has identified bioactive fragments of complement C3 and C5 as causal markers of age-related macular degeneration (AMD) progression. These components stimulate the development of wet AMD, and their presence in drusen may indicate high risk for progression.